In Vitro and In Vivo Effect of 5-FC Combined Gene Therapy with TNF-α and CD Suicide Gene on Human Laryngeal Carcinoma Cell Line Hep-2

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chai, Li Ping ^a   Wang, Zhang Feng ^a   Liang, Wei Ying ^b   Chen, Lei ^c   Chen, Dan ^c   Wang, An Xun ^c   Zhang, Zhao Qiang ^d  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSFECTION; HEP 2 CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SUICIDE GENE THERAPY; TUMOR GROWTH;

ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CLONING, MOLECULAR; CYTOSINE DEAMINASE; DNA PRIMERS; ESCHERICHIA COLI; FLUCYTOSINE; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EUKARYOTA; MUS;

EID: 84876111906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061136     Document Type: Article

References (24)

1. Uslu C, Taysi S, Akcay F, Sutbeyaz MY, Bakan N, (2003) Serum Free and Bound Siali Acid and Alpha-l-Acid Glycoprotein in Patients with Laryngeal Cancer. Annals of Clinical & Laboratory Science 33: 156-159.
2. Tamarit Conejeros JM, Carrasco Llatas M, Estellés Ferriol E, Fernández Martínez S, Baviera Granell N, et al. (2007) Supraglottic and glottic carcinomas. Study of the incidence in the last 31 years. Acta Otorrinolaringol Esp 58(10): 449-453.
3. Shang C, (2003) Advances in Molecular Cytogenetics of Laryngeal Carcinoma on Foreign Medical Science: Subvolume of Internal Medicine. Subvolume of Genetics 26(6): 360-363.
4. Hawkins NV, (1975) The treatment of glottic carcinoma:an analysis of 800 cases. Laryngoscope 85: 1485-1493.
5. Shah JP, Tollefsen HR, (1974) Epidermoid carcinoma of the supraglottic larynx.Role of neck dissection in initial surgical treatment. Am J Surg. 128: 494-499.
6. Jesse RH, (1975) The evaluation of treatment of patient with extensive squamous cancer of the vocal cords.Laryngoscope. 85: 1424-1429.
7. Trzcieniecka-Green A, Bargiel-Matusiewicz K, Borczyk J, (2007) Quality of life of patients after laryngectomy. J Physiol Pharmacol 58 Suppl 5: 699-704.
8. Rosenberg SA, (1990) Gene therapy of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene coding for TNF. Human Gene Ther 1(4): 441-480.
9. Uslu C, Taysi S, Akcay F, Sutbeyaz MY, Bakan N, (2003) Serum Free and Bound Siali Acid and Alpha-l-Acid. Glycoprotein in Patients with Laryngeal Cancer. Annals of Clinical & Laboratory Science 33: 156-159.
10. Sambrook J, Fritsch EF, Maniatis T (1999) Molecular Cloning: A Laboratory Manual.2nd ed. Beijing: Science Press 16-26, 50-56.
11. Eric J Hall, (2003) The bystander effect. Health Physics 85(1): 31-35.
12. Situ ZQ, Wu JZ, Zhang KH (2007) Cell Cultrure. Xi'an: World Books Publishing House 173-174.
13. Hawkins NV, (1975) The treatment of glottic carcinoma:an analysis of 800 cases.Laryngoscope. 85: 1485-1493.
14. Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, et al. (1997) Virally Directed Cytosine Deaminase/5-Fluorocytosine Gene Therapy Enhances Radiation Response in Human Cancer Xenografts. Cancer Res 57: 4205-4209.
15. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, et al. (1996) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferon. Cancer Res 46: 3990-3993.
16. Asher A, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA, (1987) Studies on the anti- tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974.
17. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R, et al. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (rTNA alpha). Int J Cancer 57: 656-663.
18. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, et al. (1995) Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 55: 4824-4829.
19. Hallahan DE, Vokes EE, Rubin SJ, O'Brien S, Samuels B, et al. (1995) Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am 1: 204-209.
20. Liu J, Zou WG, Lang MF, Luo J, Sun LY, et al. (2002) Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int-J-Oncol 21(3): 661-6.
21. Topf N, Worgall S, Hackett NR, Crystal RG, (1998) Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 5(4): 507-13.
22. Cao X, Huang X, Ju DW, Zhang W, Hamada H, et al. (2000) Enhanced antitumoral effect of adenovirus- mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Gene Ther 7(2): 177-186.
23. Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, et al. (1997) Virally directed cytosine deaminase/5--fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 57(19): 4205-4209.
24. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, et al. (2002) The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene-Ther 9(13): 844-849.